Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Most Lexapro (escitalopram) side effects such as nausea, headache, drowsiness, jitteriness, and sleep changes are temporary, easing within one to two weeks as your body adjusts, and usually resolving by four to six weeks. Some effects, including sexual side effects, weight changes, or excessive sweating, can persist for as long as you take the medication and may need a dose adjustment or a different antidepressant. Timelines vary based on your dose, how recently you started or increased it, other medications, and your individual metabolism, so there are several important factors to consider before assuming a side effect will fade on its own. See below for the full breakdown of typical timelines, warning signs that need prompt medical attention, and what to discuss with your prescriber.
If you are unsure whether what you feel is a passing adjustment period, a sign your dose needs revisiting, or something unrelated to Lexapro entirely, a free, instant, online symptom check can help you sort through your symptoms in minutes and understand which next step, watchful waiting or a call to your doctor, makes the most sense for you.
Last reviewed for medical accuracy: 09/15/2025
Lexapro (escitalopram) is a commonly prescribed selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety. Like other SSRIs, it can cause side effects as your body adjusts. Knowing what to expect—and when—can help you manage those effects without undue worry. This guide focuses on lexapro side effects, how long they typically last, and what you can do if they persist.
When you start Lexapro, your body needs time to adapt to changes in serotonin balance. Most side effects appear within the first few days of treatment:
These early effects are usually mild to moderate and tend to improve quickly.
During the first one to two weeks, many patients notice:
Tips for this phase:
By weeks two to four, the initial side effects usually taper off. You may start noticing the antidepressant benefits around week three:
However, some side effects can emerge or persist:
If side effects remain bothersome after four weeks, talk with your doctor about possible dose adjustments.
From one to two months onward, Lexapro’s therapeutic effects should become more noticeable, and most side effects will have faded. At this point:
If you still experience common lexapro side effects after eight weeks, it may indicate the need for medical review.
| Side Effect | Typical Duration |
|---|---|
| Nausea | 1–2 weeks |
| Headache | 1–3 weeks |
| Dizziness/lightheadedness | 1–2 weeks |
| Insomnia or drowsiness | 1–4 weeks |
| Fatigue | 1–3 weeks |
Most people find that these effects subside entirely by the end of the second month of treatment.
Some side effects can continue beyond two months or emerge later in treatment:
• Sexual dysfunction (decreased libido, delayed orgasm)
• Weight changes (gain or loss)
• Mild tremors or sweating
These effects may require specific management strategies:
If persistent effects significantly impair your quality of life, it’s important to speak with your healthcare provider.
Although uncommon, some lexapro side effects can be serious:
If you or someone you know experiences life-threatening or serious symptoms, seek immediate medical help. Always report any new or worsening mental health symptoms to your doctor.
To minimize lexapro side effects and support your well-being:
If you’re ever unsure about a symptom, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Always involve your healthcare provider when:
Never stop Lexapro abruptly; tapering under medical supervision reduces the risk of withdrawal effects. Your doctor can help you balance the benefits of treatment against any uncomfortable side effects.
If you have any questions about lexapro side effects or find them hard to manage, remember to speak to a doctor for personalized advice. Your health and safety come first.
(References)
* Brown JT, Eum S, Cook EH, Bishop JR. Pharmacogenomics of autism spectrum disorder. Pharmacogenomics. 2017 Mar;18(4):403-414. doi: 10.2217/pgs-2016-0167. Epub 2017 Feb 22. PMID: 28244813.
* MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health. 2018 Mar;24(1):11-18. doi: 10.1177/2053369117731172. Epub 2017 Oct 10. PMID: 28994639.
* Prabhakar D, Sablaban I. Escitalopram-Induced Rash. Prim Care Companion CNS Disord. 2019 Jan 31;21(1). doi: 10.4088/PCC.18l02302. Epub 2019 Jan 31. PMID: 30806996.
* Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 5. PMID: 33549697.
* Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM, Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021 Aug 5;13(3):387-401. doi: 10.3390/neurolint13030038. Epub 2021 Aug 5. PMID: 34449705; PMCID: PMC8395812.
* Conde SL, Nazha H, Simpkins C. Escitalopram Induced Angioedema. Cureus. 2022 Nov;14(11):e31600. doi: 10.7759/cureus.31600. Epub 2022 Nov 17. PMID: 36540519; PMCID: PMC9758958.
* Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy. 2023 Jul;43(7):675-690. doi: 10.1002/phar.2767. Epub 2023 Jan 27. PMID: 36651686; PMCID: PMC10378577.
* Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Ruaño G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 Jul;114(1):51-68. doi: 10.1002/cpt.2903. Epub 2023 May 30. PMID: 37032427; PMCID: PMC10564324.
* Sepúlveda-Lizcano L, Arenas-Villamizar VV, Jaimes-Duarte EB, García-Pacheco H, Paredes CS, Bermúdez V, Rivera-Porras D. Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review. Eur J Investig Health Psychol Educ. 2023 Aug 12;13(8):1505-1520. doi: 10.3390/ejihpe13080110. Epub 2023 Aug 12. PMID: 37623307; PMCID: PMC10453914.
* Rissardo JP, Fornari Caprara AL, Bhal N, Repudi R, Zlatin L, Walker IM. Drug-Induced Myoclonus: A Systematic Review. Medicina (Kaunas). 2025 Jan 15;61(1). doi: 10.3390/medicina61010131. Epub 2025 Jan 15. PMID: 39859113; PMCID: PMC11767161.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.